Bellerophon Therapeutics recently provided an update on the clinical development of INOpulse as a treatment for pulmonary arterial hypertension (PAH),…
Articles by Alice Melão, MSc
A molecular mechanism involving the tight balance between two proteins — Gal-1 and CaV1.2 — was found to regulate the…
Horizon 2020, the European Union’s prestigious research and innovation program, recently awarded ATXA Therapeutics €2.5 million ($2.91 million) to…
Scottish patients with pulmonary arterial hypertension (PAH) can now be treated with Actelion‘s Uptravi (selexipag) through the country’s …
Reata Pharmaceuticals is currently recruiting participants for its Phase 3 CATALYST trial assessing the effectiveness of bardoxolone methyl in…
A gene called FoxM1 was seen to be an important regulator of the vascular remodeling process involved in pulmonary hypertension.
Surgery to repair congenital heart defects leads to longer survival in patients with pulmonary arterial hypertension (PAH) caused by…
University of Edinburgh researchers identifying a protein that could become a target for treating pulmonary arterial hypertension, or PAH. They…
The genetic landscape of pulmonary arterial hypertension that strikes in childhood differs from the one that develops after a person…
A protein called KLF15 has an important protective role in the lung, according to the findings of Johns Hopkins…
Bellerophon Therapeutics is advancing the clinical trials program of its inhaled INOpulse nitric oxide therapy for pulmonary hypertension (PH) associated…
Computer software combined with artificial intelligence can generate advanced imaging techniques for serious diseases such as pulmonary hypertension (PH), improving…